Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lung Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 81 Carboplatin 76 Magnetic Resonance Spectroscopy 73 Specimen Handling 69 Cisplatin 62 Paclitaxel 55 Gemcitabine 46 Fluorouracil 37 Dexamethasone 37 Radiation 36 Docetaxel 36 Cyclophosphamide 36 Radiotherapy 35 Pemetrexed 35 Doxorubicin 35 Oxaliplatin 33 Leucovorin 33 Bevacizumab 31 Capecitabine 28 Vincristine 27 durvalumab 26 Etoposide 24 Rituximab 23 Taxes 22 Irinotecan 22 Nivolumab 21 Letrozole 21 Prednisone 20 Biopsy 20 Platinum 18

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × zipalertinib × 30 days × Clear all

NCT07128199 2026-05-05

REZILIENT4

Taiho Oncology, Inc.

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡